How to treat Mycoplasma pneumoniae infection in children?

If children develop this disease, it is a microbial infection, which has been on the rise in recent years. Its characteristic is that it can survive without a cell wall. According to clinical research, Mycoplasma pneumoniae is one of the common pathogens, accounting for 10% of all respiratory infections. In addition to respiratory diseases, it can also cause complications in other systems, such as hepatitis, pneumonia, nephritis, etc.

Studies have shown that in recent years, due to changes in people's lifestyles and the widespread use of antibiotics, the incidence of Mycoplasma pneumoniae infection in children has shown a significant upward trend, which has attracted great attention from medical workers. Mycoplasma pneumoniae is mainly transmitted through droplets. When the human body inhales Mycoplasma pneumoniae through droplets, it can slide into the crypts of fiber hair cells and tightly bind to the neuraminic acid receptors of the human respiratory mucosal epithelial cells, thereby effectively resisting the ciliary clearance function in the human body and avoiding phagocytosis of phagocytes.

Mycoplasma pneumoniae adheres to the epithelial cells of the respiratory mucosa and destroys them, and can release a variety of toxic metabolites, such as proteases, hydrogen peroxide, ammonia, and neurotoxins, causing lesions in the patient's respiratory tract. Studies have shown that although most Mycoplasma pneumoniae exert their pathogenicity outside human cells, a few Mycoplasma pneumoniae can invade host cells or fuse with them, causing lesions. Mycoplasma mainly causes pathogenic effects on the human respiratory tract, so children often show clinical diseases such as upper respiratory tract infection, pneumonia, bronchitis or tracheitis.

The clinical manifestations of lower respiratory tract infections caused by Mycoplasma pneumoniae in infants and young children may not have typical characteristics and are often accompanied by dyspnea or wheezing. Studies have shown that in addition to causing lung damage, Mycoplasma pneumoniae infection can also cause certain damage to the child's extrapulmonary systems, such as skin and mucous membranes, nervous system, blood system, cardiovascular system, urinary system, digestive system, as well as joint and muscle damage. Since Mycoplasma pneumoniae has no cell wall, it can be treated with antibiotics that have a significant inhibitory effect on bacterial protein synthesis, such as macrolides, aminoglycosides, tetracyclines, and quinolones, which can have a more effective clinical effect.

Children are a special group whose organs are not fully developed, so when choosing drugs, we must avoid adverse effects on their development. In addition to causing respiratory tract lesions, the infection may also invade other parts of the body. The doctor will make a comprehensive assessment of the child's condition based on the child's clinical manifestations and examination results, and select appropriate treatment drugs to ultimately achieve the desired treatment effect.